Scientific deep-dive

What GIP Does on Its Own

Tirzepatide's advantage is usually credited to its GIP component. Researchers infused native GIP for six weeks, raising total GIP in the blood about thirtyfold, and blood sugar did not improve.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

Tirzepatide acts on two receptors, and its advantage over drugs acting on one is usually credited to the second: GIP. Researchers infused native GIP for six weeks, alone and on top of semaglutide, raising total GIP in the blood roughly thirtyfold. Blood sugar did not improve.[1] That is the second study to find GIP doing very little for glucose in people, and it leaves an open question about why tirzepatide works.

What was done

Sixty-one people with type 2 diabetes were randomized into four groups (placebo alone, GIP alone, semaglutide alone, and semaglutide plus GIP) for six weeks of continuous subcutaneous infusion, double-blind.

The exposure achieved was not marginal. Fasting bioactive GIP rose from around 7 pmol/L on placebo to 45 on GIP alone and 85 alongside semaglutide; total GIP went from 14 to 375 and 527 respectively. Whatever this study failed to find, it did not fail for want of drug.

Effect on 14-day average glucose from continuous sensor monitoring. Positive numbers mean glucose went up.[1]
ComparisonEstimated effect97.5% CIP
GIP vs placebo+0.80 mmol/L−0.18 to 1.800.13
GIP added to semaglutide+0.05 mmol/L−0.85 to 0.951.00

The trial had set a target of a 1.50 mmol/L improvement, and neither comparison came close. The second row is as flat a result as this kind of analysis produces, with a P value of 1.00 and an interval sitting symmetrically around zero.

Thirty times the total GIP in the blood, and the glucose line did not move.

The second study to say this

We covered a phase 1 trial of a long-acting GIP receptor agonist, which produced dose-dependent weight loss but whose effect on fasting glucose was transient and no longer significantly different from placebo by day 29. That is in the drugs that are not here yet.

Two independent studies, two entirely different ways of raising GIP signaling, and the same answer. Infuse the native hormone for six weeks: no glucose benefit. Give a purpose-built long-acting agonist: a glucose effect that fades within a month. The consistent finding is that GIP’s contribution in humans is not a glycemic one.

This matters because GIP is an incretin, a hormone named for its ability to stimulate insulin release after eating. Its glucose-lowering role is the reason anyone was interested in it. In people with type 2 diabetes, it appears not to deliver that. Its clearest effect may lie outside the pancreas: in people whose pancreas had been removed, blocking the GIP receptor blunted the drop in bone breakdown after a meal.

So what is tirzepatide's GIP component doing?

This is the question the result raises and does not answer. Tirzepatide beats semaglutide substantially on weight (20.2% against 13.7% in the head-to-head), and the dual mechanism is the usual explanation. If GIP does nothing, the explanation needs revisiting.

  • It may act on weight rather than glucose. The long-acting agonist study found exactly that pattern: weight loss without a durable glycemic effect. This trial measured glucose.
  • A long-acting agonist is not the native hormone. Engineered molecules can differ from natural ligands in how strongly they bind, how long they stay and how the receptor responds. Those differences change the biology.
  • A continuous infusion is not a physiological signal. GIP is released in pulses after meals. Flooding the system steadily may not reproduce what pulses do.
  • The receptor may be desensitized in type 2 diabetes, which is a long-standing hypothesis and would explain a null in exactly this population.

None of those is established. The GIP contribution to tirzepatide is less well understood than the confident explanations suggest. Amgen’s experimental MariTide makes the puzzle sharper: it blocks the GIP receptor and still produced large weight loss in phase 2 (see MariTide: what the evidence shows).

What limits the trial

  • Sixty-one people at a single center over six weeks, with 16% discontinuing. The authors state that the dropouts constrain what they can conclude.
  • Every participant self-reported as White, which is the systematic pattern set out in who was actually in the trials.
  • It measured glucose, not weight. A null on one endpoint is not a null on the other.
  • Median diabetes duration was 6.3 years with a median HbA1c of 54 mmol/mol, which is reasonably controlled disease with less room to improve.

Injection site reactions were the commonest adverse event at 36%, which is what a six-week continuous infusion produces and not a property of the hormone.

Frequently Asked Questions

Not in this trial. Six weeks of continuous native GIP infusion, raising total GIP in the blood roughly thirtyfold, produced no improvement in average glucose either alone or added to semaglutide. The point estimate for GIP alone pointed slightly the wrong way.
Yes. A phase 1 trial of a long-acting GIP receptor agonist found weight loss but a glucose effect that was transient and gone by day 29. Two different ways of raising GIP signaling reached the same conclusion.
That is the open question. The GIP component may act on weight rather than glucose, an engineered agonist may behave differently from the native hormone, a continuous infusion may not reproduce pulsatile signaling, or the receptor may be desensitized in type 2 diabetes. None is established.
No. This trial measured blood sugar in people with reasonably controlled diabetes. It says nothing about GIP's contribution to weight loss, which is where the drug's main advantage lies.
Sixty-one participants at one center over six weeks, with 16% discontinuing, and all self-reporting as White. The authors note the dropouts limit their conclusions.

References

  1. 1.Helsted MM, Fonnesbech-Wulff C, Schaltz NL, et al. Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial The Lancet Diabetes & Endocrinology. 2026. PMID: 42173109.

A Weight Drug for Having Too Little Fat

Lipodystrophy is the opposite of obesity: people are missing fat tissue, and are severely metabolically ill because of it. In a cohort given tirzepatide, those with familial partial lipodystrophy cut their daily insulin by a median of 109 units.

6 min read

The Top Dose Keeps Not Being Worth It

Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.

7 min read

A Composite Is Only Its Components

A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.

7 min read

One Injection Instead of Twenty-Eight

Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.

6 min read

Tirzepatide in Ten- to Seventeen-Year-Olds

Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.

6 min read

A Quarter the Odds of Being Offered It

People with diabetes who also have a mental health diagnosis received worse care on almost every measure, and a quarter of the odds of being prescribed a GLP-1, while having half again the odds of being put on insulin.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

9.1

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

From $59/mo + membership

Get started →
Read full review →
6.4

MyDrHank

An oral route if you will not self-inject

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →